Price
$41.39+47.24%Social Signal Score
Analyst Ratings
20 analystsRevenue
$154.45M+275.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael H. Carrel
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 1,350
- Beta
- 1.21
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 9.71
Financials
Revenue
$154.45M+275.3%Net Income
$4.06MEBITDA
$9.49MFree Cash Flow
$23.93MEPS (diluted)
$0.08Shares Outstanding (diluted)
49.83M+56.7%Operating Expenses
$115.00MCash & Debt
$187.03MReturn of Capital
$543.0KRevenue by Segment (annual)
$2.45MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $534.53M | $-11.45M | $-0.24 |
| 2024 | $465.31M | $-44.70M | $-0.95 |
| 2023 | $399.25M | $-30.44M | $-0.66 |
| 2022 | $330.38M | $-46.47M | $-1.02 |
| 2021 | $274.33M | $50.20M | $1.11 |
| 2020 | $206.53M | $-48.16M | $-1.14 |
| 2019 | $230.81M | $-35.19M | $-0.94 |
| 2018 | $201.63M | $-21.14M | $-0.62 |
| 2017 | $174.72M | $-26.89M | $-0.83 |
| 2016 | $155.11M | $-33.34M | $-1.05 |
| 2015 | $129.75M | $-27.21M | $-0.97 |
| 2014 | $107.45M | $-16.21M | $-0.61 |
| 2013 | $81.89M | $-11.46M | $-0.56 |
| 2012 | $70.25M | $-7.53M | $-0.47 |
Valuation
ATRChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-12.50%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·13d ago·Positive
AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference Transcript AtriCure, Inc. ( ATRC ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Angela Wirick - Chief Financial Officer Conference Call Participants Patrick Andrew Wood - UBS Investment Bank, Research Division Presentation Patrick Andrew Wood UBS Investment Bank, Research Division Welcome. Thanks, everyone.
View source ↗ - Newsseekingalpha.com·14d ago·Positive
…coming catalysts include the STS quality metric rollout in 2027, BoxX-NoAF trial results in spring 2027, and the LeAAPS trial, all supporting institutional adoption. ATRC achieved GAAP profitability, with Q3 revenue up 15% year-over-year and adjusted EBITDA up 50.6%, signaling strong operating leverage and healthy cash generation.
View source ↗ - Newsbenzinga.com·18d ago·Positive
AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results AtriCure, Inc. (NASDAQ:ATRC) on Tuesday posted upbeat results for the third quarter.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
AtriCure, Inc. (ATRC) Q3 2026 Earnings Call Transcript AtriCure, Inc. ( ATRC ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLC Matthew O'Brien - Piper Sandler & Co., Research Division John Young - Canaccord Genuity Corp., Research Division Marie Thibault - BTIG, LLC, Research Division Lilia-Celine Lozada - JPMorgan Chase & C…
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What AtriCure (ATRC) Said on Its Q3 Earnings Call AtriCure NASDAQ: ATRC reported third-quarter 2026 revenue of $154.5 million, up 15% from a year earlier, as growth in its U.S. open ablation, appendage management and pain management businesses helped lift profitability.
View source ↗ - Newszacks.com·19d ago·Negative
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·19d ago·Neutral
AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates AtriCure (ATRC) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.01 per share a year ago.
View source ↗ - Newsfool.com·71d ago·Negative
AtriCure CTO Sells 3,657 Shares The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.
View source ↗ - Newszacks.com·74d ago·Positive
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue? AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newsseekingalpha.com·93d ago·Positive
AtriCure: Promising Cardiovascular Surgical Platform AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
View source ↗ - Newsgurufocus.com·103d ago·Positive
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95 On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
View source ↗ - Newsfool.com·107d ago·Neutral
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.
View source ↗ - Newsfool.com·107d ago·Negative
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.
View source ↗
Earnings
Tue, Feb 16(in 3 months)
Consensus estimate $-0.01 per share
Typical surprise +97.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.17 vs $-0.06beat
- Thu, Jul 23$0.18 vs $-0.00beat
- Tue, May 5$0.00 vs $-0.07beat
- Tue, Feb 17$0.06 vs $-0.04beat
- Wed, Oct 29$-0.01 vs $-0.11beat
- Tue, Jul 29$-0.13 vs $-0.15beat
Estimates and results for ATRC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATRC officers and directors.
- Bought
- —
- Sold
- $6.0m
0 trades
26 trades
- Johnson B Kristinesold
- Privitera Salvatoresold
- Privitera Salvatoresold
- Groves Regina Esold
- Privitera Salvatoresold
- Privitera Salvatoresold
- Dahlquist Karl S.sold
- Prange Karensold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (13d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (22d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2025 (34d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 15, 2024 (27d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (21d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 15, 2021 (37d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 13, 2020 (13d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 16, 2020 (16d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2020 (18d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Dec 11, 2019 (34d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Jul 12, 2019 (15d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA39 · disclosed Jun 18, 2019 (41d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
